Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0154059 (
Esophagus
)
2,950
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The transcription factor
E2F-1
, a downstream regulator of the p16-cyclinD-Rb pathway, is required for cell cycle progression. Evidence shows that overexpression of
E2F-1
can either promote or inhibit the development of tumors, depending on tissue or experimental conditions. However, the clinical impact of
E2F-1
expression on esophageal squamous cell carcinoma (ESCC) remains unknown. To analyze
E2F-1
expression in ESCC, we investigated the immunoreactivity of
E2F-1
and its correlation with clinicopathological features in 122 patients who underwent surgical resection for ESCC. Positive
E2F-1
immunostaining was detected in 73 patients (59.8%). Positive
E2F-1
immunostaining correlated positively with pathologic stage (P = 0.0103), p-Grade (P = 0.0014) and pT (P = 0.0192). The overall survival rate was worse in patients with
E2F-1
-positive tumors than in patients with
E2F-1
-negative tumors (P = 0.0290). Over-expression of
E2F-1
is associated with tumor progression and a worse prognosis after surgery in ESCC.
Dis
Esophagus
2004
PMID:Over-expression of E2F-1 in esophageal squamous cell carcinoma correlates with tumor progression. 1523 Jul 29